Nasdaq:NTRA
Natera, Inc.
Natera is a pioneering genomics company delivering high-accuracy non-invasive prenatal testing and cancer diagnostics through proprietary sequencing technology.
Key Metrics
Investment Thesis
Bull Case
Natera offers compelling growth potential as its proprietary technology dominates key markets like NIPT and cancer liquid biopsy, positioning it for significant market share expansion. The company's diverse product portfolio reduces reliance on any single segment, providing stability against regulatory or reimbursement headwinds in specific areas. Strategic partnerships and a robust pipeline of new indications could drive future profitability once R&D investments translate into widespread commercial adoption.
Bear Case
The persistent net losses over the last five years, with 2025 seeing only a slight improvement from 2024, raise concerns about the company's ability to achieve sustainable profitability in the near term. High capital expenditures and aggressive R&D spending are eroding cash reserves, which decreased from $945.6M to $1.08B while operating expenses exceeded $3 billion combined. Intense competition and potential regulatory setbacks could further delay revenue growth, making the stock risky for value-oriented investors seeking immediate earnings turnaround.
About Natera, Inc.
Natera, Inc. is a leading genomic testing company providing non-invasive prenatal testing (NIPT), cancer diagnostics, and cellular monitoring solutions to healthcare providers globally. The company leverages proprietary technologies to deliver high-accuracy genetic insights across oncology, women's health, and rare disease markets. With substantial investments in research and development, Natera aims to expand its comprehensive genomic testing portfolio and accelerate clinical adoption.
Analysis
Management Discussion
While revenue grew strongly to $2.31B in 2025, the company reported a net loss of $208.2M, reflecting continued high investments in R&D totaling $624.1M and share-based compensation of $354.4M. Operating cash flow remained positive at $215.3M despite capital expenditures reaching $106.2M, suggesting effective management of working capital which increased by $84.1M. The widening deficit in operating profit compared to gross profit highlights the substantial costs associated with scaling genomic operations and developing new assay platforms.
Industry Overview
The genomic testing industry is rapidly evolving with increasing demand for non-invasive diagnostics in prenatal care, oncology, and rare diseases driven by advances in sequencing technology. Market leaders are focusing on high-accuracy assays that require minimal sample input, creating opportunities for companies with proprietary platforms to capture premium pricing. Regulatory frameworks continue to tighten, requiring rigorous validation studies before new tests can enter the commercial market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $820.2M | $1.08B | $1.70B | $2.31B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $820.2M | $1.08B | $1.70B | $2.31B |
| Operating Expenses | $1.36B | $1.53B | $1.92B | $2.62B |
| Operating Income | $-541.0M | $-446.2M | $-222.3M | $-309.9M |
| R&D | $316.4M | $320.7M | $404.1M | $624.1M |
| G&A | $588.6M | $618.3M | $841.3M | $1.18B |
| Stock-Based Comp | $152.4M | $191.8M | $274.4M | $354.4M |
| D&A | $16.7M | $24.1M | $31.0M | $41.8M |
| Depreciation | $16.7M | $22.7M | $27.2M | $36.5M |
| Amortization | — | — | — | $3.9M |
| Other OpEx | $456.3M | $589.8M | $673.8M | $814.7M |
| Non-Operating Income | $-5.8M | $11.7M | $32.6M | $41.8M |
| Interest Expense | $9.3M | $12.6M | $10.7M | $4.1M |
| Pre-Tax Income | $-546.8M | $-434.5M | $-189.7M | $-268.1M |
| Income Tax | $978.0K | $271.0K | $695.0K | $-59.9M |
| Continuing Ops | $-547.8M | $-434.8M | $-190.4M | $-208.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-547.8M | $-434.8M | $-190.4M | $-208.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-547.8M | $-434.8M | $-190.4M | $-208.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.21B | $1.26B | $1.38B | $1.50B |
| Cash & Equivalents | $466.0M | — | — | — |
| Marketable Securities | $432.3M | $236.9M | $22.7M | — |
| Accounts Receivable | $244.4M | $278.3M | $314.2M | $296.5M |
| Inventory | $35.4M | $40.8M | $44.7M | $68.4M |
| Prepaid Expenses | $33.6M | $60.5M | $48.6M | $55.8M |
| Other Current Assets | $86.0K | $642.1M | $945.6M | $1.08B |
| Long-Term Assets | $182.7M | $183.2M | $284.9M | $901.4M |
| PP&E (Net) | $92.5M | $111.2M | $162.0M | $241.2M |
| Intangibles | — | — | — | $373.7M |
| Goodwill | — | — | — | $141.1M |
| Operating Leases | $71.9M | $56.5M | $86.1M | $108.5M |
| Other LT Assets | $18.3M | $15.4M | $36.7M | $36.9M |
| Total Assets | $1.39B | $1.44B | $1.66B | $2.40B |
| Current Liabilities | $310.5M | $307.3M | $344.0M | $441.2M |
| Accounts Payable | $31.1M | $15.0M | $34.9M | $33.2M |
| Current Leases | $7.6M | $11.6M | $10.2M | $15.6M |
| Deferred Revenue | $10.8M | $16.6M | $19.8M | $24.9M |
| Other Current Liab | $260.9M | $264.0M | $279.2M | $367.6M |
| Long-Term Liabilities | $378.2M | $369.1M | $121.3M | $244.7M |
| LT Operating Leases | $76.6M | $67.0M | $96.6M | $118.5M |
| Other LT Liab | $281.7M | $282.9M | $7.8M | $109.2M |
| Total Liabilities | $688.7M | $676.4M | $465.3M | $685.9M |
| Shareholders' Equity | $705.7M | $765.3M | $1.20B | $1.71B |
| Retained Earnings | $-1.94B | $-2.38B | $-2.57B | $-2.78B |
| AOCI | $-16.4M | $-3.1M | $-344.0K | $-258.0K |
| Total L&E | $1.39B | $1.44B | $1.66B | $2.40B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-547.8M | $-434.8M | $-190.4M | $-208.2M |
| Non-Cash Adjustments | $-75.5M | $113.5M | $265.8M | $339.3M |
| Working Capital Changes | $191.8M | $74.4M | $60.2M | $84.1M |
| Cash from Operations | $-431.5M | $-247.0M | $135.7M | $215.3M |
| Capital Expenditures | $47.7M | $39.2M | $66.4M | $106.2M |
| Cash from Investing | $330.3M | $168.5M | $137.6M | $-132.2M |
| Cash from Financing | $482.6M | $254.5M | $30.2M | $47.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $381.5M | $176.0M | $303.5M | $130.6M |
| Beginning Cash | $84.6M | $466.1M | $642.1M | $945.6M |
| Ending Cash | $466.1M | $642.1M | $945.6M | $1.08B |
Frequently Asked Questions
How does Natera, Inc. make money?
The company's revenue streams primarily consist of Non-Invasive Prenatal Testing (NIPT) serving women and fetal medicine centers, Cancer Diagnostics including liquid biopsy assays for oncology, and Cellular Monitoring solutions for tracking genetic mutations in conditions like sickle cell disease. Additional revenue comes from Rare Disease testing and specialized genomic services supporting clinical trials and research.
What are the main risks for NTRA?
Significant regulatory hurdles and potential delays in FDA approvals for new diagnostic tests could stall product launches and revenue growth. The high level of research and development expenses combined with current net losses indicates a heavy burn rate that relies on successful commercialization of future products. Intense competition from established players and emerging biotech firms may pressure pricing margins and market share in crowded genomic testing segments. Dependence on reimbursement policies from government payers and private insurers creates uncertainty regarding long-term demand for expensive diagnostic procedures.
What is NTRA's competitive advantage?
Natera holds a strong proprietary advantage through its high-sensitivity sequencing technology that detects low levels of fetal DNA and cancer biomarkers, offering superior accuracy over traditional methods. The company benefits from a robust pipeline of approved and in-development tests across multiple therapeutic areas, creating diversified revenue beyond prenatal care. A large installed base of healthcare partners and established brand recognition in the genetic testing space provide significant barriers to entry for new competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.